Biopolymer conjugates comprising an interleukin-11 analog
US8716446B2 · kind B2 · utility
4Cited by
2References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 21, 2009 |
| Grant date | May 6, 2014 |
| Priority date | — |
| Expiry date | Jun 6, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.